IgA nephropathy, palmoplantar pustulosis, sleep apnea syndrome, tonsillar hypertrophy tonsillar focal disease, palatotonsillectomy, lymphocyte, Haemophilus Parainfluenzae
Conditions
Interventions
None listed
Sponsors
Kaneko Fumie
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients who have indicated for palatotonsillectomy for the treatment of IgA nephropathy as tonsillar focal disease. (2) Patients who have indicated for palatotonsillectomy for the treatment of palmoplantar pustulosis as tonsillar focal disease. (3) Patients who have indicated for palatotonsillectomy with sleep apnea syndrome or enlarged palatine tonsils to relieve upper airway stenosis.
Exclusion criteria
Exclusion criteria: (1) Patients with enlarged tonsils due to neoplastic lesions such as malignant tumors (tonsil cancer, malignant lymphoma, etc.) and benign tumors (papilloma of the pharynx), or suspected patients (2) Patients undergoing emergency palatotonsillectomy due to severe bacterial infection such as peritonsillar abscess and recurrent tonsillitis (3) Other patients deemed inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) Medical record information Age, sex, name of the disease for which palato- tonsillectomy was indicated, blood test results, and bacterial test results (taken from tonsil crypts and tonsil parenchyma). (2) Information obtained from the removed tonsil tissue and peripheral blood 1. Bacteriological profile of the tonsil crypts and surface by comprehensive genetic analysis. 2. Quantitative analysis of gene expression by single cell analysis of tonsils and peripheral blood mononuclear cells. 3. Quantitative analysis of gene expression in tonsils and peripheral blood mononuclear cells after CpG-ODN stimulation by single cell analysis. | — |
Contacts
Public ContactFumie Kaneko
Wakayama Medical University
Outcome results
None listed